Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells
Ivan Cohen(Hospital of the University of Pennsylvania), Kostas Stamatopoulos(Centre for Research and Technology Hellas), Bria Fulmer(Translational Therapeutics (United States)), Vijay Bhoj(Hospital of the University of Pennsylvania), S. Schuster(Hospital of the University of Pennsylvania), Ositadimma Ugwuanyi(Hospital of the University of Pennsylvania), Andreas Agathangelidis(Aristotle University of Thessaloniki), Elisavet Vlachonikola(Aristotle University of Thessaloniki), Alessia Santi(University of Perugia), Anastasia Iatrou(Centre for Research and Technology Hellas), Giulia Gabrielli(Hospital of the University of Pennsylvania), Jaryse Harris(Hospital of the University of Pennsylvania), Guido Ghilardi(Hospital of the University of Pennsylvania), Chih Hao Wu(National Institutes of Health), Puneeth Guruprasad(Parker Institute for Cancer Immunotherapy), Scott A. Jenks(Emory University), David Espie(Hospital of the University of Pennsylvania), Regina Bugrovsky(Emory University), Enrico Tiacci(University of Perugia), Jean Lemoine(Hospital of the University of Pennsylvania), Marcos Cases(Hospital of the University of Pennsylvania), Patrizia Porazzi(Hospital of the University of Pennsylvania), Brontë Kolar, Evgeny Arons(National Institutes of Health), Maria Karipidou(Centre for Research and Technology Hellas), Igñacio Sanz(Emory University), Federico Stella(University of Milan), Sokratis A. Apostolidis(University of Pennsylvania), Portia A. Kreiger(Children's Hospital of Philadelphia), Audrey Bochi-Layec(University of Pennsylvania), Ki Hyun Kim(Hospital of the University of Pennsylvania), Ranjani Ramasubramanian(University of Pennsylvania), Yunlin Zhang(Hospital of the University of Pennsylvania), RJ Kreitman(National Institutes of Health), Matthew B. Palmer(University of Pennsylvania), Huiwu Zhao(Hospital of the University of Pennsylvania), Giovanni Medico(NewYork–Presbyterian Hospital), Luca Paruzzo(Hospital of the University of Pennsylvania), Sarah McCuaig(Children's Hospital of Philadelphia), Paolo Ghia(Vita-Salute San Raffaele University), Raymone Pajarillo(Hospital of the University of Pennsylvania), Giorgio Inghirami(Cornell University), Pedram Bayat(Hospital of the University of Pennsylvania), Aditya Bhosale(Hospital of the University of Pennsylvania), S. Cenk Sahinalp(National Institutes of Health), Edward M. Behrens(Children's Hospital of Philadelphia), Li-Ping Wang(Hospital of the University of Pennsylvania), Chi‐Ping Day(National Institutes of Health), E. John Wherry(University of Pennsylvania), Eleni Bouziani(National and Kapodistrian University of Athens)
Cited by 10
Related Papers
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
|Science|2021|876
Comprehensive mapping of immune perturbations associated with severe COVID-19
|Science Immunology|2020|806
Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19
|Nature Immunology|2020|791